Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LINC01605 Is a Novel Target of Mutant p53 in Breast and Ovarian Cancer Cell Lines.
Coan M, Toso M, Cesaratto L, Rigo I, Borgna S, Dalla Pietà A, Zandonà L, Iuri L, Zucchetto A, Piazza C, Baldassarre G, Spizzo R, Nicoloso MS. Coan M, et al. Among authors: nicoloso ms. Int J Mol Sci. 2023 Sep 6;24(18):13736. doi: 10.3390/ijms241813736. Int J Mol Sci. 2023. PMID: 37762037 Free PMC article.
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Gambelli A, Nespolo A, Rampioni Vinciguerra GL, Pivetta E, Pellarin I, Nicoloso MS, Scapin C, Stefenatti L, Segatto I, Favero A, D'Andrea S, Mucignat MT, Bartoletti M, Lucia E, Schiappacassi M, Spessotto P, Canzonieri V, Giorda G, Puglisi F, Vecchione A, Belletti B, Sonego M, Baldassarre G. Gambelli A, et al. Among authors: nicoloso ms. EMBO Mol Med. 2024 May;16(5):1162-1192. doi: 10.1038/s44321-024-00069-3. Epub 2024 Apr 24. EMBO Mol Med. 2024. PMID: 38658801 Free PMC article.
Author Correction: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Gambelli A, Nespolo A, Rampioni Vinciguerra GL, Pivetta E, Pellarin I, Nicoloso MS, Scapin C, Stefenatti L, Segatto I, Favero A, D'Andrea S, Mucignat MT, Bartoletti M, Lucia E, Schiappacassi M, Spessotto P, Canzonieri V, Giorda G, Puglisi F, Vecchione A, Belletti B, Sonego M, Baldassarre G. Gambelli A, et al. Among authors: nicoloso ms. EMBO Mol Med. 2024 Aug;16(8):1981. doi: 10.1038/s44321-024-00099-x. EMBO Mol Med. 2024. PMID: 38997596 Free PMC article.
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.
Brisotto G, Montico M, Turetta M, Zanussi S, Cozzi MR, Vettori R, Boschian Boschin R, Vinante L, Matrone F, Revelant A, Palazzari E, Innocente R, Fanetti G, Gerratana L, Garutti M, Lisanti C, Bolzonello S, Nicoloso MS, Steffan A, Muraro E. Brisotto G, et al. Among authors: nicoloso ms. Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276. Viruses. 2023. PMID: 37376576 Free PMC article.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Lorusso D, Pignata S, Tamberi S, Mangili G, Bologna A, Nicoloso MS, Giolitto S, Salutari V, Mantero M, Pisano C, Bergamini A, Musacchio L, Ronzulli D, Raspagliesi F, Scambia G. Lorusso D, et al. Among authors: nicoloso ms. Gynecol Oncol. 2022 Dec;167(3):436-443. doi: 10.1016/j.ygyno.2022.09.023. Epub 2022 Oct 8. Gynecol Oncol. 2022. PMID: 36220670 Clinical Trial.
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M, Giorda G, Viel A, Fornasarig M, Zdjelar A, Segatto E, Sorio R, Corsetti S, Scalone S, Nicoloso MS, Pivetta T, Lucia E, Clemente N, Palazzari E, Canzonieri V, Puglisi F. Bartoletti M, et al. Among authors: nicoloso ms. Curr Oncol. 2022 Jul 22;29(8):5209-5212. doi: 10.3390/curroncol29080413. Curr Oncol. 2022. PMID: 35892982 Free PMC article.
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra GL, Dall'Acqua A, Bomben R, Perin T, Cusan M, Schiappacassi M, Gerratana L, D'Andrea S, Citron F, Vit F, Musco L, Mattevi MC, Mungo G, Nicoloso MS, Sonego M, Massarut S, Sorio R, Barzan L, Franchin G, Giorda G, Lucia E, Sulfaro S, Giacomarra V, Polesel J, Toffolutti F, Canzonieri V, Puglisi F, Gattei V, Vecchione A, Belletti B, Baldassarre G. Viotto D, et al. Among authors: nicoloso ms. J Pathol. 2021 Feb;253(2):234-245. doi: 10.1002/path.5584. Epub 2020 Dec 4. J Pathol. 2021. PMID: 33140857 Free PMC article.
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.
Bartoletti M, Mazzeo R, De Scordilli M, Del Fabro A, Vitale MG, Bortot L, Nicoloso MS, Corsetti S, Bonotto M, Scalone S, Giorda G, Sorio R, Andreetta C, Meacci ML, De Vivo R, Fasola G, Sopracordevole F, Puglisi F. Bartoletti M, et al. Among authors: nicoloso ms. Int J Gynecol Cancer. 2020 Nov;30(11):1672-1677. doi: 10.1136/ijgc-2020-001771. Epub 2020 Sep 30. Int J Gynecol Cancer. 2020. PMID: 32998859
52 results